首页> 外文期刊>European journal of endocrinology >DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing’s syndrome
【24h】

DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing’s syndrome

机译:内分泌疾病的诊断:去氨加压素试验在库欣综合征的诊断和随访中的作用

获取原文
       

摘要

Desmopressin is a vasopressin analogue selective for type 2 vasopressin receptors that mediate renal water retention. In contrast to the native hormone arginine vasopressin, a well-known ACTH secretagogue, desmopressin, exerts minimal or no activity on ACTH excretion. However, in a substantial proportion of patients with ACTH-dependent Cushing’s syndrome (CS), desmopressin elicits an ACTH and cortisol response, which contrasts with the minimal responses obtained in healthy subjects. The mechanism underlying this paradoxical response involves upregulation of vasopressin type 3 and/or the aberrant expression of type 2 receptors by neoplastic ACTH-producing cells. This makes desmopressin administration a suitable test enabling the distinction between neoplastic from functional (formerly termed ‘pseudo-Cushing syndrome’) ACTH-dependent cortisol excess. Several studies have now established an adjunctive role of desmopressin in the initial diagnostic workup of CS. Despite some early data indicating that this test may also have a role in distinguishing between Cushing’s disease (CD) and ectopic ACTH secretion, subsequent studies failed to confirm this observation. The ability of the paradoxical response to desmopressin to depict the presence of neoplastic ACTH-secreting cells was also exploited in the follow-up of patients with CD undergoing surgery. Loss of the desmopressin response, performed in the early postoperative period, was a good predictor for a favorable long-term outcome. Moreover, during follow-up, reappearance of desmopressin paradoxical response was an early indicator for recurrence. In conclusion, the desmopressin test is a valid tool in both the diagnosis and follow-up of patients with CD and should be more widely applied in the workup of these patients.
机译:去氨加压素是一种对2型加压素受体具有选择性的血管加压素类似物,其介导肾水滞留。与天然激素精氨酸加压素相反,众所周知的促肾上腺皮质激素促分泌素去氨加压素对促肾上腺皮质激素的排泄作用很小或没有作用。但是,在相当一部分患有ACTH依赖型库欣综合征(CS)的患者中,去氨加压素会引起ACTH和皮质醇反应,这与健康受试者获得的最低反应相反。产生这种反常应答的机制涉及增生ACTH的细胞上调3型加压素和/或2型受体的异常表达。这使去氨加压素的给药成为一项合适的测试,可以区分赘生性肿瘤与功能性(以前称为“假性库欣综合征”)ACTH依赖性皮质醇过量。现在有几项研究确定了去氨加压素在CS的初始诊断检查中的辅助作用。尽管一些早期数据表明该测试也可能在区分库欣氏病(CD)和异位ACTH分泌中起作用,但随后的研究未能证实这一发现。在接受CD手术的患者的随访中,还利用了对去氨加压素的自相矛盾反应来描述肿瘤中ACTH分泌细胞的存在。在术后早期进行的去氨加压素反应的丧失是良好的长期预后的良好预测指标。此外,在随访期间,去氨加压素反常应答的重新出现是复发的早期指标。总之,去氨加压素测试是诊断和随访CD患者的有效工具,应在这些患者的检查中得到更广泛的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号